Several studies have showed that BRCA1/2 mutations occur at scattered sites and occur as missense mutations, of which will especially influence those situated in exon-encoding domains that interact with BRCA1-binding proteins, such as BARD1, BRIP1 and PALB2, which (along with RAD51C, RAD51D and possibly RAP80 and FAM175A, encoding Abraxas) are also breast and/or ovarian cancer-susceptibility genes [34,35]. This evidence concerns the gene ABRAXAS1 and ovarian cancer.